

PRODUCT	DISEASE	PIPELINE			
		PHASE 1	PHASE 2	PHASE 3	COMMERCIAL
TTR					
ONPATTRO® (patisiran)	hATTR Amyloidosis with Polyneuropathy				
AMVUTTRA® (vutrisiran)	ATTR Amyloidosis with Cardiomyopathy and hATTR Amyloidosis with Polyneuropathy				
Nucesiran (ALN-TTRsc04)	ATTR Amyloidosis				
RARE					
GIVLAARI® (givosiran)	Acute Hepatic Porphyria (AHP)				
OXLUMO® (lumasiran)	Primary Hyperoxaluria Type 1 (PH1)				
Qfitlia™ (fitusiran)	Hemophilia A or B¹				
Cemdisiran (+/- Pozelimab)	Myasthenia Gravis¹				
Cemdisiran (+ Pozelimab)	Paroxysmal Nocturnal Hemoglobinuria¹				
ALN-6400	Bleeding Disorders				
CARDIOVASCULAR					
Leqvio® (inclisiran)	Hypercholesterolemia¹				
Zilebesiran	Hypertension²				
Zilebesiran + REVERSIR	Hypertension²				
METABOLIC					
Rapirosiran (ALN-HSD)	Metabolic Dysfunction-Associated Steatohepatitis (MASH)¹				
ALN-4324	Type 2 Diabetes Mellitus				
ALN-PNP	Non-Alcoholic Fatty Liver Disease (NAFLD)³				
ALN-APOC3	Dyslipidemia¹				
ALN-CIDEB	Metabolic Dysfunction-Associated Steatohepatitis (MASH)¹				
NEUROLOGIC					
Mivelsiran (ALN-APP)	Cerebral Amyloid Angiopathy (CAA)⁴				
Mivelsiran (ALN-APP)	Alzheimer's Disease ⁴				
ALN-HTT02	Huntington's Disease⁵				
ALN-SOD	SOD1 Amyotrophic Lateral Sclerosis (ALS)³				
OTHER					
Cemdisiran (+/- Pozelimab)	Geographic Atrophy¹				
Elebsiran (+Tobevibart)	Hepatitis D Virus Infection¹				
ALN-BCAT	Hepatocellular Carcinoma				
ALN-ANG3	Healthy Volunteers¹				
ALN-F1202	Healthy Volunteers¹				

1 Out-licensed with milestones and/or royalties
2 Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US
3 Partner-led with profit split

4 Product developed as part of a collaboration with Regeneron
5 Partnered, Alnylam-led with profit split

Alnylam Clinical Development Pipeline as of May 2025